View Future GrowthBio-Techne 過去の業績過去 基準チェック /06Bio-Techneの収益は年間平均-14.4%の割合で減少していますが、 Life Sciences業界の収益は年間 増加しています。収益は年間4.9% 5.1%割合で 増加しています。 Bio-Techneの自己資本利益率は5.3%であり、純利益率は9%です。主要情報-14.40%収益成長率-14.60%EPS成長率Life Sciences 業界の成長26.83%収益成長率5.12%株主資本利益率5.25%ネット・マージン9.04%前回の決算情報31 Mar 2026最近の業績更新お知らせ • Oct 15Bio-Techne Corporation to Report Q1, 2026 Results on Nov 05, 2025Bio-Techne Corporation announced that they will report Q1, 2026 results at 12:30 PM, US Eastern Standard Time on Nov 05, 2025Reported Earnings • Aug 06Full year 2025 earnings released: EPS: US$0.47 (vs US$1.07 in FY 2024)Full year 2025 results: EPS: US$0.47 (down from US$1.07 in FY 2024). Revenue: US$1.22b (up 5.2% from FY 2024). Net income: US$73.4m (down 56% from FY 2024). Profit margin: 6.0% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.Reported Earnings • May 08Third quarter 2025 earnings released: EPS: US$0.14 (vs US$0.31 in 3Q 2024)Third quarter 2025 results: EPS: US$0.14 (down from US$0.31 in 3Q 2024). Revenue: US$316.2m (up 4.2% from 3Q 2024). Net income: US$22.6m (down 54% from 3Q 2024). Profit margin: 7.1% (down from 16% in 3Q 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.すべての更新を表示Recent updatesお知らせ • May 07Bio-Techne Corporation announces Quarterly dividend, payable on May 29, 2026Bio-Techne Corporation announced Quarterly dividend of USD 0.0800 per share payable on May 29, 2026, ex-date on May 18, 2026 and record date on May 18, 2026.お知らせ • Apr 18Bio-Techne Corporation Introduces Streamlined Brand Architecture With Three Portfolio BrandsBio-Techne Corporation announced a streamlined brand architecture designed to enable scientists and clinicians to more easily find the answers they need based on their application and stage of research. The company has organized its products and technologies under three focused portfolio brands -- R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™ -- aligning its solutions with the way modern science progresses from early discovery through translational insights to clinical diagnostics. The portfolio brands will debut at the AACR Annual Meeting 2026 and AAI's IMMUNOLOGY 2026™. The R&D Systems portfolio brings together Bio-Techne's trusted proteins, antibodies, immunoassays, small molecules and innovative instruments used by scientists worldwide. R&D Systems solutions help researchers generate reproducible results, validate discoveries, and advance early-stage research towards clinical application with confidence. R&D Systems provides dependable tools needed to explore, experiment, and uncover new biological insights. R&D Systems also provides key GMP-grade reagents and tools essential for advancing cell and gene therapy workflows. The Bio-Techne Spatial portfolio leverages technologies that help researchers and clinicians translate biology and disease context across both the gold-standard RNAscope™ in situ hybridization technology and the automated COMET™ spatial hyperplex platform. Bio-Techne Spatial solutions enable scalable, high-resolution visualization of RNA and protein with multiomic analysis, delivering exceptional sensitivity and precision to reveal differences in cell structure, identify clinically relevant biomarkers, inform pathology-driven research questions and accelerate therapeutic discovery. The Bio-Techne Diagnostics portfolio provides clinical laboratories and IVD manufacturers with assay kits, IVD-grade reagents, antibodies, molecular controls, calibrators, and proficiency-testing materials needed to design, develop, and validate reliable diagnostic assays. The portfolio supports the full lifecycle of assay development from early design through deployment at scale. By delivering high-quality raw materials and comprehensive assay solutions, Bio-Techne Diagnostics helps ensure accuracy, strengthens clinical decision-making, and ultimately contributes to improved patient outcomes. Together, these three portfolios create a clearer, more connected path for customers by providing a streamlined, end-to-end view of Bio-Techne's solutions, aligning tools and technologies from discovery through translation to clinical diagnostics and accelerating scientific and clinical progress. R&D Systems™ now includes the legacy brands Novus Biologicals™, Tocris Bioscience™, and ProteinSimple™; Bio-Techne Spatial now includes the legacy brands Lunaphore™, and Advanced Cell Diagnostics™; Bio-Techne Diagnostics now includes Asuragen®, Bionostics, Cliniqa, RNA Medical®, and R&D Systems™ Clinical Controls.お知らせ • Mar 25Bio-Techne Corporation Expands Comet Solution Portfolio with Addition of Spyre Focus Panels and Spyre Amplification KitsBio-Techne Corporation announced the expansion of its COMET solution portfolio with the addition of the new SPYRE Focus Panels and SPYRE Amplification Kits. Together, these strengthen the COMET technology modular, automated spatial biology workflow, delivering expanded flexibility, greater sensitivity, and enabling deeper, more focused interrogation of biologically meaningful data from initial assay design through final interpretation. To support these updates, new features of HORIZON Image Analysis Software have also been introduced, tailored for COMET hyperplex images using the new SPYRE tools, further streamlining tissue analysis. SPYRE Antibody Panels, including the newly introduced Stroma and Vessel Focused Panels, are modular antibody panels designed to enable flexible multiplex assay design while reducing optimization time. Panels leverage validated antibodies with ready-to-use protocols to streamline setup while maintaining flexibility to incorporate markers from a lab's own antibody library. SPYRE Amplification Kits use seqLA technology to improve the detection of low-abundance and difficult-to-detect targets. Together, SPYRE Focus Panels and SPYRE Amplification Kits strengthen Bio-Techne's commitment to deliver a fully integrated, modular, and automated spatial biology ecosystem that accelerates research and preclinical therapeutic development. These innovations continue to empower researchers to generate richer data and deeper biological understanding from every tissue sample.お知らせ • Feb 16Bio-Techne's Ella Platform Achieves Ce-Ivd Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical LaboratoriesBio-Techne Corporation announced that the Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, helping laboratories streamline workflows and support timely decision-making. Ella is a compact, cartridge-based immunoassay system that delivers accurate biomarker results in under 90 minutes with minimal hands-on time. By simplifying the manual steps of traditional immunoassays, Ella reduces operator variability and provides high-quality, reproducible data suitable for both translational research and clinical applications. The platform is compatible with Simple Plex™? assays, which remain for research use only, and are powered by R&D Systems antibodies and proteins. With more than 390 analytes across neuroscience, immunology, oncology, and cell and gene therapy, the Simple Plex portfolio enables researchers to maintain consistency and data quality while working efficiently across a wide range of applications. With CE-IVD marking now in place, hospitals, clinical laboratories, or other European organizations may use Ella as a validated platform for in-house test development, clinical trials, or other translational activities. Diagnostic assay developers may also develop clinical applications on the Ella CE-IVD validated platform. The certification enhances confidence in Ella's performance and supports Bio-Techne's long-term goal to advance precision medicine by providing dependable, standardized solutions for biomarker detection.お知らせ • Feb 11Bio-Techne Corporation Announces Executive Changes, Effective March 1, 2026Bio-Techne Corporation announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition. Steve Crouse, currently Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026. Steve has over two decades of experience as a senior life sciences leader at various companies. As Senior Vice President, Analytical Solutions Division, he is responsible for Bio-Techne's portfolio of protein analysis instruments and immunoassays and has driven strategic initiatives, successfully launched several innovative platforms and delivered strong growth during his four-year tenure. Before joining Bio-Techne, he most recently served as General Manager of Thermo Fisher Scientific's Protein Detection and Quantification business unit. He has an MBA from the Marshall School of Business at the University of Southern California and a M.S. in Biochemistry from Georgetown University.お知らせ • Feb 04Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2025, Payable on February 27, 2026Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2025. The quarterly dividend will be payable February 27, 2026, to all common shareholders of record on February 16, 2026.お知らせ • Feb 03Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with A Fully Defined Synthetic AlternativeBio-Techne Corporation announced the launch of Cultrex™? Synthetic Hydrogel, a fully defined synthetic extracellular matrix (ECM) designed to support reproducible and scalable 3D stem cell and organoid research. The new product expands Bio-Techne's established Cultrex ECM portfolio, offering researchers a synthetic alternative that reduces lot-to-lot variability while supporting translational and regulatory-aligned research workflows alongside the Company's widely used traditional matrices. Cultrex Synthetic Hydrogel is designed to support the use of 3D organoid models across a wide range of applications, including drug screening, toxicology and personalized medicine, reducing the reliance on animal-component derived matrices and supporting the broader utilization of new approach methodologies (NAMs). By avoiding the biological variability inherent in traditional ECMs, the hydrogel helps researchers standardize experimental conditions across studies and laboratories, enabling more consistent and reliable organoid culture. Cultrex Synthetic Hydogel aligns with the FDA's broader goal of driving innovation to improve translational outcomes by offering a more reliable platform for preclinical research. With the regulatory drive for increased adoption of NAMs across the pharmaceutical industry, researchers increasingly require tools that improve the scalability, consistency, and documentation surrounding organoid workflows. The Cultrex Synthetic HydrogEL launch represents an important step toward the broader adoption of organoid models in support of translational and regulatory- aligned research. Its controlled composition supports consistency and traceability as programs advance toward regulatory-facing studies. This launch further expands Bio-Techne's robust portfolio of solutions for stem cell and organoid culture, including Cultrex Basement Membrane Extracts (BME), as well as recombinant cytokines and growth factors, AI-modified proteins, small molecules, media, and supplements. Together, these offerings provide researchers with the flexibility to select ECM solutions aligned with their experimental, scalability, and regulatory needs.お知らせ • Jan 28Bio-Techne Launches Simple Plex Ultra- Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological BiomarkersBio-Techne Corporation announced the launch of Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform. Early detection of neurodegenerative disease biomarkers has historically been limited by their extremely low abundance in accessible biofluids such as blood. The new, ultrasensitive assays overcome this barrier by delivering step-change improvements on the Ella platform in analytical sensitivity and reliable quantification of key biomarkers, including NFL, GFAP, pTau 217, and Amyloid b (aa1-42). This capability enables researchers to detect subtle, early biological changes that are often missed, accelerating insights into disease onset, progression, and treatment response. The assays build on Ella's proven performance, which is cited in more than 200 peer-reviewed neurology-focused publications and widely adopted in translational and clinical research, driving breakthrough diagnostic and therapeutic advances. Ella's automated workflow reduces manual steps and variability, delivering ultrasensitive assay results with an overall runtime of under three hours. These assays are intended for Research Use Only. This launch strengthens Bio-Techne's immunoassay leadership by combining ultrasensitive proteomic assays with automated instrumentation that improves reproducibility, throughput, and data quality. The Ella platform has been cited in more than 1,000 peer-reviewed publications. Bio-Techne's broad proteomic and spatial biology portfolio continues to drive breakthroughs in neuroscience research and advance precision medicine.お知らせ • Dec 09Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein AnalysisBio-Techne Corporation announced the expanded launch and first shipment of its next-generation Leo System, powered by Simple Western Technology. The enhanced Leo System introduces dual-channel fluorescence detection alongside chemiluminescence, expanding data throughput and efficiency, and generating greater insights from precious samples. Fluorescence adds a fourth multiplexing option to its molecular weight separation, RePlex, and resampling capabilities to create even more experimental flexibility and tackle complex biological questions. This advance enables researchers to simultaneously quantify targets with distinct expression levels, assess different proteoforms, such as phosphorylated and total protein forms, in the same capillary, multiplex same-weight targets in a single run, and process up to 100 capillaries within three hours.お知らせ • Nov 05Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2025, Payable on November 28, 2025Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2025. The quarterly dividend will be payable November 28, 2025, to all common shareholders of record on November 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis.お知らせ • Nov 04Bio-Techne Corporation and Nucleai Announces the Presentation of Pivotal Data from the SECOMBIT Clinical Trial at the Society for Immunotherapy of Cancer 2025 Annual MeetingBio-Techne Corporation and Nucleai announced the presentation of pivotal data from the SECOMBIT clinical trial at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The study, conducted in collaboration with Professor Paolo Ascierto, Full Professor of Oncology at the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, showcases the significance of spatial biology in translational research by combining, for the first time, an immuno-oncology (IO) multiplex immunofluorescence (mIF) panel with advanced AI-driven multimodal biomarker analysis. Using the COMET platform and a 28-plex mIF panel, researchers profiled 42 pre-treatment biopsies from patients with metastatic melanoma. Nucleai's multimodal spatial operating system integrated high-plex imaging, histopathology, and clinical outcome data to identify distinct immune cell interactions that correlate with progression-free survival (PFS), overall survival (OS), and clinical benefit across three treatment arms incorporating Immune Checkpoint Blockade (ICB). Key Findings: Arm A (MAPKi - ICB): Immune activation markers such as PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells are linked to better outcomes. Arm B (ICB - MAPKi): PD-1+ CD8 T- cells in the tumor invasive margin and their interactions with PD-L1+ CD4 T-cells correlated with improved survival. Arm C (MAPKi - IC B - MAPKi): APC-T-cell interactions in tumor margins associated with better outcomes; macrophage interactions in outer tumor microenvironment (TME) indicated poorer prognosis. The study shows that where immune cells are located and how they interact within the tumor matters significantly for treatment success. By using AI and spatial biology to map these immune niches, researchers can better predict which patients will benefit from specific therapies moving toward more personalized and effective cancer treatment. Availability at SITC 2025 Bio-Techne's full spatial biology portfolio--including the new ProximityScope™? assay and the extended SPYRE™? portfolio will be showcased at Booth #603 at SITC 2025. Visual data from the SECOMBIT study will also be presented in Poster # 528, alongside additional immuno-oncology research from Bio-Techne and its collaborators.お知らせ • Oct 28Bio-Techne Launches ProximityScope Assay on the Bond Rx Platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions ResearchBio-Techne Corporation announced the launch of the ProximityScope™ assay, a spatial solution developed for seamless integration with the BOND RX staining platform from Leica Biosystems. This powerful combination enables researchers to visualize functional protein-protein interactions on fixed tissue with subcellular resolution - bringing Leica's automation excellence from Leica Biosystems to the forefront of spatial biology. The ProximityScope assay provides a clear, visual signal only when two proteins of interest are physically close, revealing previously inaccessible insights into biological mechanisms. Designed to work in tandem with the BOND RX stained system from Leica Biosystems, the assay also integrates with ACD's RNAscope Multiomic LS kit, enabling enhanced detection of RNA and protein on the same tissue section. This offers scientists a uniquely powerful tool for both discovery and translational research, sparing precious tissue while delivering novel insights. Traditional methods for studying protein interactions, such as bulk pull-down assays or non-spatial proximity assays, lack localization data or require dissociation cells that lose their spatial orientation. ProximityScope addresses this gap by combining high sensitivity with high specificity and low background, providing unparalleled accuracy and confidence in results. Key applications include visualizing cell-cell interactions for studying immune checkpoints or bispecific antibodies, analyzing cell surface interactions that activate signaling pathways, evaluating antibody-based therapeutics for toxicity and target specificity, and investigating intracellular interactions involved in transcriptional activation.お知らせ • Oct 15Bio-Techne Corporation to Report Q1, 2026 Results on Nov 05, 2025Bio-Techne Corporation announced that they will report Q1, 2026 results at 12:30 PM, US Eastern Standard Time on Nov 05, 2025お知らせ • Sep 26Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical ApplicationsBio-Techne Corporation announced new advancements in its spatial biology portfolio for the RNAscope™? ISH technology and the Lunaphore COMET™?. These solutions help researchers and pathologists bridge the gap between translational research and clinical applications by enabling the detection of RNA and protein biomarkers on the same tissue section. RNAscope™? empowers pathologists and histologists to detect clinically relevant biomarkers--such as viral markers, secreted proteins, point mutations, and chromosomal translocations--within routine anatomic pathology workflows. COMET™? offers fully automated, high-throughput hyperplex analysis of both RNA and protein biomarkers, accelerating spatial multiomic workflows and enabling deeper biological insights. Scientific investigations presented this fall explore the potential of facilitating the diagnostic utility of these technologies. Studies include the use of RNAscope™? for assessing B-cell clonality with IGLL5 detection, and COMET™? for spatial profiling of lymphoid malignancies using a 21-plex seqIF™? panel. These findings demonstrate how spatial biology tools can be integrated into diagnostic workflows, especially in cases with limited tissue availability. Bio-Techne will showcase these innovations at the National Society of Histotechnology (NSH) Convention, taking place September 26-30 in Long Beach, CA. Advanced Cell Diagnostics (ACD) and Lunaphore will exhibit at booths #139 and #427, respectively. Presentations include: RNAscope™? for Routine Anatomic Pathology: Dr. Ryan Bremer will highlight the advantages of RNAscope™? over legacy RNA ISH and other methods for well-known markers and new markers of potential clinical significance, as well as the easy adoption of RNAscope into existing workflows. (Session WS29, Sep. 27, 4:45 p.m.) RNAscope™? of IGLL5 Offers New Insights in B-cell Clonality: Dr. Ishani Das has been selected for a live presentation of her poster focusing on the comparative performance of RNAscope™? for assess B-cell clonality using immunoglobulin kappa and lambda light chain markers, emphasizing the value of concurrent detection of IGLL5 only offered by RNAscope. seqIF™? Panel for Spatial Profiling of Lymphoid Malignancies: Dr. Antonio Sorrentino will present a poster showcasing the COMET technology's potential in improving the diagnosis of lymphoid malignancies, utilizing clinically validated antibodies with a 21-plex (seqIF™?) panel that integrates into the workflow of B-cell lymphomas and conserves valuable tissue from biopsies. Bio-Techne and Leica Biosystems continue to advance their partnership by co-hosting a waterfront reception at Park's Lighthouse on September 28, offering attendees a chance to network and explore RNAscope assays on Leica BOND platforms.お知らせ • Sep 22+ 1 more updateBio-Techne Corporation, Annual General Meeting, Oct 30, 2025Bio-Techne Corporation, Annual General Meeting, Oct 30, 2025.New Risk • Aug 24New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 62% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.0% net profit margin).Reported Earnings • Aug 06Full year 2025 earnings released: EPS: US$0.47 (vs US$1.07 in FY 2024)Full year 2025 results: EPS: US$0.47 (down from US$1.07 in FY 2024). Revenue: US$1.22b (up 5.2% from FY 2024). Net income: US$73.4m (down 56% from FY 2024). Profit margin: 6.0% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.お知らせ • Aug 06Bio-Techne Corporation Declares Dividend for the Quarter Ended June 30, 2025, Payable on August 29, 2025Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2025. The quarterly dividend will be payable August 29, 2025, to all common shareholders of record on August 18, 2025.お知らせ • May 12Bio-Techne Corporation to Showcase Next-Generation Solutions for Gene and Cell Therapy At American Society of Gene & Cell Therapy 2025Bio-Techne Corporation announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the American Society of Gene & Cell Therapy 2025 meeting taking place in New Orleans between May 13th - 17th at the New Orleans Ernest N. Memorial Convention Center. Bio-Techne will feature its cutting-edge advancements for cell and gene therapy development and manufacturing at booth 1537. Highlights include the new RNAscope protease-free workflow for visualization of biodistribution of AAV vectors, transgene mRNA, small RNAs (ASO, siRNA, miRNA) along with functional RNA and protein markers. Bio-Techne's booth will also showcase its solutions to improve cell therapy workflows, including the ProPak GMP cytokines in dose-optimized, single-use bags with weldable tubing for closed-system cell therapy manufacturing, and new AI-modified, designer proteins. The next-generation Simple Western Leo System will also be featured, with this instrument enabling the simultaneous processing of up to 100 samples in a single 3-hour run. Leading researchers along with Maithreyan Srinivasan, PhD, Chief Scientific Officer, Advanced Cell Diagnostics, a Bio-Techne brand, will present the latest innovations with RNAscope technology at ACD's symposium on May 14th at 8:30 am in room 383-385. This session will highlight NextGen RNAscope Multiomics Solutions for Spatial Precision: AAV, small RNA, CAR-T, and Beyond.Reported Earnings • May 08Third quarter 2025 earnings released: EPS: US$0.14 (vs US$0.31 in 3Q 2024)Third quarter 2025 results: EPS: US$0.14 (down from US$0.31 in 3Q 2024). Revenue: US$316.2m (up 4.2% from 3Q 2024). Net income: US$22.6m (down 54% from 3Q 2024). Profit margin: 7.1% (down from 16% in 3Q 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.収支内訳Bio-Techne の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BIT:1TECH 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 261,2111093979731 Dec 251,216814419830 Sep 251,2177845010030 Jun 251,220734469931 Mar 251,2091324959231 Dec 241,1961584529930 Sep 241,1721514359730 Jun 241,1591684299731 Mar 241,15420341710231 Dec 231,1452244269330 Sep 231,1442474079330 Jun 231,1372853979231 Mar 231,1242714159231 Dec 221,1202623909130 Sep 221,1182924008930 Jun 221,1062723928731 Mar 221,0762253618531 Dec 211,0302103508030 Sep 219851773347630 Jun 219311403127131 Mar 218481842966731 Dec 207991752826630 Sep 207602482716530 Jun 207392292676531 Mar 207551872736531 Dec 197451952716430 Sep 19734932666430 Jun 19714962626231 Mar 197031212576031 Dec 18682962445830 Sep 186611282325730 Jun 186431262165531 Mar 186191121945531 Dec 175991141875530 Sep 17577731835430 Jun 17563761755431 Mar 17541741705131 Dec 16528821584930 Sep 165171011454730 Jun 164991041384531 Mar 164821051304431 Dec 15465991254430 Sep 154561071214330 Jun 1545210811541質の高い収益: 1TECHには$157.0M } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が31st March, 2026に影響を及ぼしています。利益率の向上: 1TECHの現在の純利益率 (9%)は、昨年(10.9%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 1TECHの収益は過去 5 年間で年間14.4%減少しました。成長の加速: 1TECHは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: 1TECHは過去 1 年間で収益成長率がマイナス ( -16.8% ) となったため、 Life Sciences業界平均 ( 5.4% ) と比較することが困難です。株主資本利益率高いROE: 1TECHの 自己資本利益率 ( 5.3% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 23:38終値2026/05/22 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bio-Techne Corporation 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26 アナリスト機関David ToungArgus Research CompanyCatherine Ramsey SchulteBairdRobert WassermanBenchmark Company23 その他のアナリストを表示
お知らせ • Oct 15Bio-Techne Corporation to Report Q1, 2026 Results on Nov 05, 2025Bio-Techne Corporation announced that they will report Q1, 2026 results at 12:30 PM, US Eastern Standard Time on Nov 05, 2025
Reported Earnings • Aug 06Full year 2025 earnings released: EPS: US$0.47 (vs US$1.07 in FY 2024)Full year 2025 results: EPS: US$0.47 (down from US$1.07 in FY 2024). Revenue: US$1.22b (up 5.2% from FY 2024). Net income: US$73.4m (down 56% from FY 2024). Profit margin: 6.0% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
Reported Earnings • May 08Third quarter 2025 earnings released: EPS: US$0.14 (vs US$0.31 in 3Q 2024)Third quarter 2025 results: EPS: US$0.14 (down from US$0.31 in 3Q 2024). Revenue: US$316.2m (up 4.2% from 3Q 2024). Net income: US$22.6m (down 54% from 3Q 2024). Profit margin: 7.1% (down from 16% in 3Q 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • May 07Bio-Techne Corporation announces Quarterly dividend, payable on May 29, 2026Bio-Techne Corporation announced Quarterly dividend of USD 0.0800 per share payable on May 29, 2026, ex-date on May 18, 2026 and record date on May 18, 2026.
お知らせ • Apr 18Bio-Techne Corporation Introduces Streamlined Brand Architecture With Three Portfolio BrandsBio-Techne Corporation announced a streamlined brand architecture designed to enable scientists and clinicians to more easily find the answers they need based on their application and stage of research. The company has organized its products and technologies under three focused portfolio brands -- R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™ -- aligning its solutions with the way modern science progresses from early discovery through translational insights to clinical diagnostics. The portfolio brands will debut at the AACR Annual Meeting 2026 and AAI's IMMUNOLOGY 2026™. The R&D Systems portfolio brings together Bio-Techne's trusted proteins, antibodies, immunoassays, small molecules and innovative instruments used by scientists worldwide. R&D Systems solutions help researchers generate reproducible results, validate discoveries, and advance early-stage research towards clinical application with confidence. R&D Systems provides dependable tools needed to explore, experiment, and uncover new biological insights. R&D Systems also provides key GMP-grade reagents and tools essential for advancing cell and gene therapy workflows. The Bio-Techne Spatial portfolio leverages technologies that help researchers and clinicians translate biology and disease context across both the gold-standard RNAscope™ in situ hybridization technology and the automated COMET™ spatial hyperplex platform. Bio-Techne Spatial solutions enable scalable, high-resolution visualization of RNA and protein with multiomic analysis, delivering exceptional sensitivity and precision to reveal differences in cell structure, identify clinically relevant biomarkers, inform pathology-driven research questions and accelerate therapeutic discovery. The Bio-Techne Diagnostics portfolio provides clinical laboratories and IVD manufacturers with assay kits, IVD-grade reagents, antibodies, molecular controls, calibrators, and proficiency-testing materials needed to design, develop, and validate reliable diagnostic assays. The portfolio supports the full lifecycle of assay development from early design through deployment at scale. By delivering high-quality raw materials and comprehensive assay solutions, Bio-Techne Diagnostics helps ensure accuracy, strengthens clinical decision-making, and ultimately contributes to improved patient outcomes. Together, these three portfolios create a clearer, more connected path for customers by providing a streamlined, end-to-end view of Bio-Techne's solutions, aligning tools and technologies from discovery through translation to clinical diagnostics and accelerating scientific and clinical progress. R&D Systems™ now includes the legacy brands Novus Biologicals™, Tocris Bioscience™, and ProteinSimple™; Bio-Techne Spatial now includes the legacy brands Lunaphore™, and Advanced Cell Diagnostics™; Bio-Techne Diagnostics now includes Asuragen®, Bionostics, Cliniqa, RNA Medical®, and R&D Systems™ Clinical Controls.
お知らせ • Mar 25Bio-Techne Corporation Expands Comet Solution Portfolio with Addition of Spyre Focus Panels and Spyre Amplification KitsBio-Techne Corporation announced the expansion of its COMET solution portfolio with the addition of the new SPYRE Focus Panels and SPYRE Amplification Kits. Together, these strengthen the COMET technology modular, automated spatial biology workflow, delivering expanded flexibility, greater sensitivity, and enabling deeper, more focused interrogation of biologically meaningful data from initial assay design through final interpretation. To support these updates, new features of HORIZON Image Analysis Software have also been introduced, tailored for COMET hyperplex images using the new SPYRE tools, further streamlining tissue analysis. SPYRE Antibody Panels, including the newly introduced Stroma and Vessel Focused Panels, are modular antibody panels designed to enable flexible multiplex assay design while reducing optimization time. Panels leverage validated antibodies with ready-to-use protocols to streamline setup while maintaining flexibility to incorporate markers from a lab's own antibody library. SPYRE Amplification Kits use seqLA technology to improve the detection of low-abundance and difficult-to-detect targets. Together, SPYRE Focus Panels and SPYRE Amplification Kits strengthen Bio-Techne's commitment to deliver a fully integrated, modular, and automated spatial biology ecosystem that accelerates research and preclinical therapeutic development. These innovations continue to empower researchers to generate richer data and deeper biological understanding from every tissue sample.
お知らせ • Feb 16Bio-Techne's Ella Platform Achieves Ce-Ivd Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical LaboratoriesBio-Techne Corporation announced that the Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, helping laboratories streamline workflows and support timely decision-making. Ella is a compact, cartridge-based immunoassay system that delivers accurate biomarker results in under 90 minutes with minimal hands-on time. By simplifying the manual steps of traditional immunoassays, Ella reduces operator variability and provides high-quality, reproducible data suitable for both translational research and clinical applications. The platform is compatible with Simple Plex™? assays, which remain for research use only, and are powered by R&D Systems antibodies and proteins. With more than 390 analytes across neuroscience, immunology, oncology, and cell and gene therapy, the Simple Plex portfolio enables researchers to maintain consistency and data quality while working efficiently across a wide range of applications. With CE-IVD marking now in place, hospitals, clinical laboratories, or other European organizations may use Ella as a validated platform for in-house test development, clinical trials, or other translational activities. Diagnostic assay developers may also develop clinical applications on the Ella CE-IVD validated platform. The certification enhances confidence in Ella's performance and supports Bio-Techne's long-term goal to advance precision medicine by providing dependable, standardized solutions for biomarker detection.
お知らせ • Feb 11Bio-Techne Corporation Announces Executive Changes, Effective March 1, 2026Bio-Techne Corporation announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition. Steve Crouse, currently Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026. Steve has over two decades of experience as a senior life sciences leader at various companies. As Senior Vice President, Analytical Solutions Division, he is responsible for Bio-Techne's portfolio of protein analysis instruments and immunoassays and has driven strategic initiatives, successfully launched several innovative platforms and delivered strong growth during his four-year tenure. Before joining Bio-Techne, he most recently served as General Manager of Thermo Fisher Scientific's Protein Detection and Quantification business unit. He has an MBA from the Marshall School of Business at the University of Southern California and a M.S. in Biochemistry from Georgetown University.
お知らせ • Feb 04Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2025, Payable on February 27, 2026Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2025. The quarterly dividend will be payable February 27, 2026, to all common shareholders of record on February 16, 2026.
お知らせ • Feb 03Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with A Fully Defined Synthetic AlternativeBio-Techne Corporation announced the launch of Cultrex™? Synthetic Hydrogel, a fully defined synthetic extracellular matrix (ECM) designed to support reproducible and scalable 3D stem cell and organoid research. The new product expands Bio-Techne's established Cultrex ECM portfolio, offering researchers a synthetic alternative that reduces lot-to-lot variability while supporting translational and regulatory-aligned research workflows alongside the Company's widely used traditional matrices. Cultrex Synthetic Hydrogel is designed to support the use of 3D organoid models across a wide range of applications, including drug screening, toxicology and personalized medicine, reducing the reliance on animal-component derived matrices and supporting the broader utilization of new approach methodologies (NAMs). By avoiding the biological variability inherent in traditional ECMs, the hydrogel helps researchers standardize experimental conditions across studies and laboratories, enabling more consistent and reliable organoid culture. Cultrex Synthetic Hydogel aligns with the FDA's broader goal of driving innovation to improve translational outcomes by offering a more reliable platform for preclinical research. With the regulatory drive for increased adoption of NAMs across the pharmaceutical industry, researchers increasingly require tools that improve the scalability, consistency, and documentation surrounding organoid workflows. The Cultrex Synthetic HydrogEL launch represents an important step toward the broader adoption of organoid models in support of translational and regulatory- aligned research. Its controlled composition supports consistency and traceability as programs advance toward regulatory-facing studies. This launch further expands Bio-Techne's robust portfolio of solutions for stem cell and organoid culture, including Cultrex Basement Membrane Extracts (BME), as well as recombinant cytokines and growth factors, AI-modified proteins, small molecules, media, and supplements. Together, these offerings provide researchers with the flexibility to select ECM solutions aligned with their experimental, scalability, and regulatory needs.
お知らせ • Jan 28Bio-Techne Launches Simple Plex Ultra- Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological BiomarkersBio-Techne Corporation announced the launch of Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform. Early detection of neurodegenerative disease biomarkers has historically been limited by their extremely low abundance in accessible biofluids such as blood. The new, ultrasensitive assays overcome this barrier by delivering step-change improvements on the Ella platform in analytical sensitivity and reliable quantification of key biomarkers, including NFL, GFAP, pTau 217, and Amyloid b (aa1-42). This capability enables researchers to detect subtle, early biological changes that are often missed, accelerating insights into disease onset, progression, and treatment response. The assays build on Ella's proven performance, which is cited in more than 200 peer-reviewed neurology-focused publications and widely adopted in translational and clinical research, driving breakthrough diagnostic and therapeutic advances. Ella's automated workflow reduces manual steps and variability, delivering ultrasensitive assay results with an overall runtime of under three hours. These assays are intended for Research Use Only. This launch strengthens Bio-Techne's immunoassay leadership by combining ultrasensitive proteomic assays with automated instrumentation that improves reproducibility, throughput, and data quality. The Ella platform has been cited in more than 1,000 peer-reviewed publications. Bio-Techne's broad proteomic and spatial biology portfolio continues to drive breakthroughs in neuroscience research and advance precision medicine.
お知らせ • Dec 09Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein AnalysisBio-Techne Corporation announced the expanded launch and first shipment of its next-generation Leo System, powered by Simple Western Technology. The enhanced Leo System introduces dual-channel fluorescence detection alongside chemiluminescence, expanding data throughput and efficiency, and generating greater insights from precious samples. Fluorescence adds a fourth multiplexing option to its molecular weight separation, RePlex, and resampling capabilities to create even more experimental flexibility and tackle complex biological questions. This advance enables researchers to simultaneously quantify targets with distinct expression levels, assess different proteoforms, such as phosphorylated and total protein forms, in the same capillary, multiplex same-weight targets in a single run, and process up to 100 capillaries within three hours.
お知らせ • Nov 05Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2025, Payable on November 28, 2025Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2025. The quarterly dividend will be payable November 28, 2025, to all common shareholders of record on November 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
お知らせ • Nov 04Bio-Techne Corporation and Nucleai Announces the Presentation of Pivotal Data from the SECOMBIT Clinical Trial at the Society for Immunotherapy of Cancer 2025 Annual MeetingBio-Techne Corporation and Nucleai announced the presentation of pivotal data from the SECOMBIT clinical trial at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The study, conducted in collaboration with Professor Paolo Ascierto, Full Professor of Oncology at the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, showcases the significance of spatial biology in translational research by combining, for the first time, an immuno-oncology (IO) multiplex immunofluorescence (mIF) panel with advanced AI-driven multimodal biomarker analysis. Using the COMET platform and a 28-plex mIF panel, researchers profiled 42 pre-treatment biopsies from patients with metastatic melanoma. Nucleai's multimodal spatial operating system integrated high-plex imaging, histopathology, and clinical outcome data to identify distinct immune cell interactions that correlate with progression-free survival (PFS), overall survival (OS), and clinical benefit across three treatment arms incorporating Immune Checkpoint Blockade (ICB). Key Findings: Arm A (MAPKi - ICB): Immune activation markers such as PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells are linked to better outcomes. Arm B (ICB - MAPKi): PD-1+ CD8 T- cells in the tumor invasive margin and their interactions with PD-L1+ CD4 T-cells correlated with improved survival. Arm C (MAPKi - IC B - MAPKi): APC-T-cell interactions in tumor margins associated with better outcomes; macrophage interactions in outer tumor microenvironment (TME) indicated poorer prognosis. The study shows that where immune cells are located and how they interact within the tumor matters significantly for treatment success. By using AI and spatial biology to map these immune niches, researchers can better predict which patients will benefit from specific therapies moving toward more personalized and effective cancer treatment. Availability at SITC 2025 Bio-Techne's full spatial biology portfolio--including the new ProximityScope™? assay and the extended SPYRE™? portfolio will be showcased at Booth #603 at SITC 2025. Visual data from the SECOMBIT study will also be presented in Poster # 528, alongside additional immuno-oncology research from Bio-Techne and its collaborators.
お知らせ • Oct 28Bio-Techne Launches ProximityScope Assay on the Bond Rx Platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions ResearchBio-Techne Corporation announced the launch of the ProximityScope™ assay, a spatial solution developed for seamless integration with the BOND RX staining platform from Leica Biosystems. This powerful combination enables researchers to visualize functional protein-protein interactions on fixed tissue with subcellular resolution - bringing Leica's automation excellence from Leica Biosystems to the forefront of spatial biology. The ProximityScope assay provides a clear, visual signal only when two proteins of interest are physically close, revealing previously inaccessible insights into biological mechanisms. Designed to work in tandem with the BOND RX stained system from Leica Biosystems, the assay also integrates with ACD's RNAscope Multiomic LS kit, enabling enhanced detection of RNA and protein on the same tissue section. This offers scientists a uniquely powerful tool for both discovery and translational research, sparing precious tissue while delivering novel insights. Traditional methods for studying protein interactions, such as bulk pull-down assays or non-spatial proximity assays, lack localization data or require dissociation cells that lose their spatial orientation. ProximityScope addresses this gap by combining high sensitivity with high specificity and low background, providing unparalleled accuracy and confidence in results. Key applications include visualizing cell-cell interactions for studying immune checkpoints or bispecific antibodies, analyzing cell surface interactions that activate signaling pathways, evaluating antibody-based therapeutics for toxicity and target specificity, and investigating intracellular interactions involved in transcriptional activation.
お知らせ • Oct 15Bio-Techne Corporation to Report Q1, 2026 Results on Nov 05, 2025Bio-Techne Corporation announced that they will report Q1, 2026 results at 12:30 PM, US Eastern Standard Time on Nov 05, 2025
お知らせ • Sep 26Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical ApplicationsBio-Techne Corporation announced new advancements in its spatial biology portfolio for the RNAscope™? ISH technology and the Lunaphore COMET™?. These solutions help researchers and pathologists bridge the gap between translational research and clinical applications by enabling the detection of RNA and protein biomarkers on the same tissue section. RNAscope™? empowers pathologists and histologists to detect clinically relevant biomarkers--such as viral markers, secreted proteins, point mutations, and chromosomal translocations--within routine anatomic pathology workflows. COMET™? offers fully automated, high-throughput hyperplex analysis of both RNA and protein biomarkers, accelerating spatial multiomic workflows and enabling deeper biological insights. Scientific investigations presented this fall explore the potential of facilitating the diagnostic utility of these technologies. Studies include the use of RNAscope™? for assessing B-cell clonality with IGLL5 detection, and COMET™? for spatial profiling of lymphoid malignancies using a 21-plex seqIF™? panel. These findings demonstrate how spatial biology tools can be integrated into diagnostic workflows, especially in cases with limited tissue availability. Bio-Techne will showcase these innovations at the National Society of Histotechnology (NSH) Convention, taking place September 26-30 in Long Beach, CA. Advanced Cell Diagnostics (ACD) and Lunaphore will exhibit at booths #139 and #427, respectively. Presentations include: RNAscope™? for Routine Anatomic Pathology: Dr. Ryan Bremer will highlight the advantages of RNAscope™? over legacy RNA ISH and other methods for well-known markers and new markers of potential clinical significance, as well as the easy adoption of RNAscope into existing workflows. (Session WS29, Sep. 27, 4:45 p.m.) RNAscope™? of IGLL5 Offers New Insights in B-cell Clonality: Dr. Ishani Das has been selected for a live presentation of her poster focusing on the comparative performance of RNAscope™? for assess B-cell clonality using immunoglobulin kappa and lambda light chain markers, emphasizing the value of concurrent detection of IGLL5 only offered by RNAscope. seqIF™? Panel for Spatial Profiling of Lymphoid Malignancies: Dr. Antonio Sorrentino will present a poster showcasing the COMET technology's potential in improving the diagnosis of lymphoid malignancies, utilizing clinically validated antibodies with a 21-plex (seqIF™?) panel that integrates into the workflow of B-cell lymphomas and conserves valuable tissue from biopsies. Bio-Techne and Leica Biosystems continue to advance their partnership by co-hosting a waterfront reception at Park's Lighthouse on September 28, offering attendees a chance to network and explore RNAscope assays on Leica BOND platforms.
お知らせ • Sep 22+ 1 more updateBio-Techne Corporation, Annual General Meeting, Oct 30, 2025Bio-Techne Corporation, Annual General Meeting, Oct 30, 2025.
New Risk • Aug 24New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 62% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.0% net profit margin).
Reported Earnings • Aug 06Full year 2025 earnings released: EPS: US$0.47 (vs US$1.07 in FY 2024)Full year 2025 results: EPS: US$0.47 (down from US$1.07 in FY 2024). Revenue: US$1.22b (up 5.2% from FY 2024). Net income: US$73.4m (down 56% from FY 2024). Profit margin: 6.0% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
お知らせ • Aug 06Bio-Techne Corporation Declares Dividend for the Quarter Ended June 30, 2025, Payable on August 29, 2025Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2025. The quarterly dividend will be payable August 29, 2025, to all common shareholders of record on August 18, 2025.
お知らせ • May 12Bio-Techne Corporation to Showcase Next-Generation Solutions for Gene and Cell Therapy At American Society of Gene & Cell Therapy 2025Bio-Techne Corporation announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the American Society of Gene & Cell Therapy 2025 meeting taking place in New Orleans between May 13th - 17th at the New Orleans Ernest N. Memorial Convention Center. Bio-Techne will feature its cutting-edge advancements for cell and gene therapy development and manufacturing at booth 1537. Highlights include the new RNAscope protease-free workflow for visualization of biodistribution of AAV vectors, transgene mRNA, small RNAs (ASO, siRNA, miRNA) along with functional RNA and protein markers. Bio-Techne's booth will also showcase its solutions to improve cell therapy workflows, including the ProPak GMP cytokines in dose-optimized, single-use bags with weldable tubing for closed-system cell therapy manufacturing, and new AI-modified, designer proteins. The next-generation Simple Western Leo System will also be featured, with this instrument enabling the simultaneous processing of up to 100 samples in a single 3-hour run. Leading researchers along with Maithreyan Srinivasan, PhD, Chief Scientific Officer, Advanced Cell Diagnostics, a Bio-Techne brand, will present the latest innovations with RNAscope technology at ACD's symposium on May 14th at 8:30 am in room 383-385. This session will highlight NextGen RNAscope Multiomics Solutions for Spatial Precision: AAV, small RNA, CAR-T, and Beyond.
Reported Earnings • May 08Third quarter 2025 earnings released: EPS: US$0.14 (vs US$0.31 in 3Q 2024)Third quarter 2025 results: EPS: US$0.14 (down from US$0.31 in 3Q 2024). Revenue: US$316.2m (up 4.2% from 3Q 2024). Net income: US$22.6m (down 54% from 3Q 2024). Profit margin: 7.1% (down from 16% in 3Q 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.